TICKERNERD
Menu
MASSMASSHealthcare · Medical Devices

MASS Stock Forecast: 908 Devices, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$9.52
+1.82% on the day

The 6 Wall Street analysts covering 908 Devices, Inc. hold a median 12-month price target of $13 — +39.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$393.5M
Ticker Nerd rank
83 / 100
Median analyst target
$13
Analysts covering
6
Revenue$16.1M+23.3% y/y
Operating income−$6.4M
Net income−$11.9M
Free cash flow$3.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.2%
1M
−4.9%
YTD
+81.3%
1Y
+66.4%
From 52W high
−14.2%
From 52W low
+87.0%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MASS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 908 Devices, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Accruals
86
Momentum
83
Quality
68
Value
60
Size
57
Revisions
48
Issuance
45
Volatility
42

Growth (87): Sales and profits are climbing, and climbing faster than before.

Volatility (42): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MASS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MASS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26MASSHigh $14Median $13Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $12Median $13High $14

The green dot is the last close — the median target sits +39.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Sept 2026Canaccord GenuityInitiatesBuy$14
12 Aug 2026Roth CapitalMaintainsBuy—
12 Aug 2026Roth CapitalMaintainsBuy$11 → $13
12 Aug 2026StifelMaintainsBuy—
12 Aug 2026StifelMaintainsBuy$10 → $12
29 July 2026Roth CapitalInitiatesBuy$11
29 July 2026Roth CapitalInitiatesBuy—
5 Aug 2025Leerink PartnersUpgradeOutperform$12
5 Aug 2025Leerink PartnersUpgradeOutperform—
15 Jan 2025Stephens & Co.ReiteratesOverweight—
13 Nov 2024Leerink PartnersDowngradeMarket Perform—
13 Nov 2024StifelMaintainsBuy—
17 Oct 2024Leerink PartnersMaintainsOutperform—
13 May 2024Stephens & Co.ReiteratesOverweight—
25 Sept 2023Stephens & Co.ReiteratesOverweight—
7 Feb 2023Stephens & Co.InitiatesOverweight—
6 Jan 2023SVB LeerinkMaintainsOutperform—
15 Nov 2022SVB LeerinkMaintainsOutperform—
8 Mar 2022SVB LeerinkMaintainsOutperform—
14 May 2021SVB LeerinkMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MASS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MASS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, 908 Devices, Inc. returned +66.4% against +17.5% for the S&P 500, dividends included.

MASS vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26MASSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MASS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

908 Devices, Inc. (MASS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.6×

Cheaper than 41% of US stocks

Price / sales
6.5×

Cheaper than 20% of US stocks

Price / book
2.7×

Cheaper than 36% of US stocks

EV / EBITDA
−18.0×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
23.3%

Higher than 73% of US stocks

Earnings growth (YoY)
23.3%

Higher than 61% of US stocks

Gross margin
51.9%

Higher than 64% of US stocks

Operating margin
−39.6%

Higher than 18% of US stocks

Net margin
−57.0%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−25.0%

Higher than 29% of US stocks

Return on assets
−6.8%

Higher than 29% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

908 Devices, Inc. (MASS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • 908 Devices, Inc. has a market value of $393.5M and an enterprise value of $296.3M.

  • Revenue in the twelve months to 30 June 2026: $60.8M. The latest quarter grew 23.3% year on year.

  • Net income over the same four quarters: −$34.7M, a −57.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.95.

  • Free cash flow in the twelve months to 30 June 2026: $615K.

  • Shares outstanding: 38.1M.

  • Trailing P/E: 17.6×; forward P/E: −31.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • 908 Devices, Inc. employs 172 people — $354K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MASS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MASS908 Devices, Inc.$393.5M
83
PACBPacific Biosciences of California, Inc.$392.6M
44
SIShoulder Innovations, Inc.$385.8M
27
CLPTClearpoint Neuro, Inc.$408.1M
20
OFIXOrthofix Medical, Inc.$353.6M
80
SGHTSight Sciences, Inc.$439.6M
90
SENSSenseonics Holdings, Inc.$454.7M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 908 Devices, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MASS news & analysis

908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium

Business Wire · 1 Sept 2026neutral

908 Devices announced that its management will present at the 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City, with the presentation scheduled for 3:45 p.m. Eastern Time and webcast for interested registrants.

Why it matters — The company's participation offers MASS watchers an opportunity to hear management discuss its handheld chemical analysis tools within the context of aerospace and defense applications.

908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates

MarketBeat · 30 Aug 2026positive

908 Devices reported second-quarter 2026 results featuring revenue growth, a narrower adjusted EBITDA loss, and increasing recurring revenue. The company also outlined its strategy to expand in handheld chemical detection and raised its 2026 outlook.

Why it matters — A raised outlook and improving financial metrics signal accelerating demand for the company's handheld detection products, a key area of its growth strategy.

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

MarketBeat · 18 Aug 2026neutral

908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago, as presented at the TG Therapeutics conference.

Why it matters — MASS watchers would care because the company is positioning itself around a concentrated handheld detection portfolio for public safety and defense after its life-sciences divestiture.

908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market

MarketBeat · 15 Aug 2026neutral

908 Devices is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement, executives said during a Canaccord Genuity discussion following the divestiture of its bioprocessing and biopharma business line.

Why it matters — The divestiture signals a strategic pivot that redefines 908 Devices' core business, so the company's go-forward revenue and growth prospects now hinge on its handheld detection segment.

908 Devices Q2: Another Solid Report

Seeking Alpha · 13 Aug 2026positive

908 Devices reported another Q2 revenue beat, with revenue up 23% year-over-year to $16.07 million and product revenue up nearly 35.5% as the installed base expanded 23%. Management raised 2026 revenue guidance to $68–$70 million while operating and net losses narrowed.

Why it matters — A MASS watcher would care because the report shows continued revenue growth, an expanding installed base, raised full-year guidance, and narrowing losses at the company.

FAQ

Frequently asked questions about MASS stock

What is the MASS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering 908 Devices, Inc. have a median 12-month price target of $13, with estimates ranging from $12 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MASS stock a buy right now?

Of the 6 analysts covering 908 Devices, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 908 Devices, Inc. 83 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MASS?

As at 12 Sept 2026, 908 Devices, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will MASS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +39.2% from the last close, and Ticker Nerd's factor model ranks 908 Devices, Inc. 83 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MASS stock forecast for 2030?

No analyst covering 908 Devices, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MASS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $14 over the next 12 months.

How has MASS stock performed over the past year?

908 Devices, Inc. returned +66.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 908 Devices, Inc. do?

908 Devices Inc. is a medical technology company that develops handheld and desktop chemical analysis instruments for point-of-need testing.

What is the latest news on MASS?

The most recent item we track (Business Wire, 1 Sept 2026): "908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium". 908 Devices announced that its management will present at the 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City, with the presentation scheduled for 3:45 p.m. Eastern Time and webcast for interested registrants.

Company

About 908 Devices, Inc.

908 Devices Inc. is a medical technology company that develops handheld and desktop chemical analysis instruments for point-of-need testing. Its product portfolio centers on portable mass spectrometry and spectroscopy systems used to detect, identify, and monitor unknown substances in demanding environments. The company’s devices support applications across health, safety, and defense, including field screening for hazardous chemicals, drugs, explosives, gases, and other materials that require rapid analysis outside traditional laboratories. 908 Devices also serves markets such as life sciences research, bioprocessing, biopharma, forensics, and industrial analysis with tools designed for faster, more accessible sample interrogation. Headquartered in Burlington, Massachusetts, 908 Devices focuses on making advanced analytical capabilities available in compact formats that can be used directly at the point of need.

CEO Dr. Kevin J. Knopp Ph.D. · 172 employees · United States · https://908devices.com